<DOC>
	<DOCNO>NCT02191007</DOCNO>
	<brief_summary>Evaluate efficacy safety Calcipotriol Betamethasone Ointment Calcipotriol Ointment sequential therapy</brief_summary>
	<brief_title>Efficacy Safety Study Calcipotriol Betamethasone Plus Calcipotriol Sequential Therapy Psoriasis</brief_title>
	<detailed_description>1.240 subject randomize 1:1:1 divide 3 group 2.Week0 Week4 , group treat Calcipotriol Betamethasone Ointment 3.Week4 Week12 , group respectively treat Calcipotriol Betamethasone Ointment , Calcipotriol Ointment Urea Cream 4.The efficacy safety evaluate baseline , well 1 , 4 , 8 12 week begin treatment .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>1 . Subjects sign Informed Consent Form； 2 . Male female subject 1865 year age； 3 . Clinically confirm diagnosis plaque psoriasis per diagnostic criterion psoriasis vulgaris specify Clinical Dermatology . 4 . Involved area 110 % body surface area . 1 . Incompliance diagnosis plaque psoriasis plaque area &gt; 10 % body surface area . 2 . Erythrodermic psoriasis , psoriasis arfhropathica pustular psoriasis ; 3 . Known allergy component test control drug； 4 . Concomitant allergic skin disease eczema， contact dermatitis urticaria , serious and/or extensive skin disease； 5 . Systemic medication ultraviolet therapy psoriasis within 4 week prior study initiation； 6 . Topical use external drug psoriasis within 2 week prior study initiation； 7 . Women childbearing potential pregnant , plan become pregnant study lactating； 8 . Glucocorticoid immunodepressant , hypoleukemia due tumor chemotherapy within last 4 weeks； 9 . Serious lifethreatening condition allow life expectancy le 2 months； 10 . Inability guarantee take medication complete visit schedule study ; 11 . Serious infection suitable external treatment； 12 . Any condition investigator deem unsuitable enter study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>